More severe hay fever symptoms experienced in urban areas
People living in urban areas experience more severe hay fever symptoms than those in rural areas, according to UK researchers. In the first study to carefully map hay fever symptoms with air quality, weather and land use, researchers found twice the severity of runny nose, sore eyes and wheezy breathing in urban areas than rural... Read moreThe post More severe hay fever symptoms experienced in urban areas appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - February 28, 2023 Category: Nursing Authors: Carolyn Scott Tags: Respiratory hay fever Source Type: news
Hay Fever Symptoms Worse in Urban Versus Rural Areas
MONDAY, Feb. 27, 2023 -- People living in urban areas report significantly worse hay fever symptoms than those living in rural areas, according to a study published online Feb. 21 in Scientific Reports.
Ann Gledson, from University of Manchester in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2023 Category: Pharmaceuticals Source Type: news
HEALTH NOTES: Hay fever is twice as fierce for urbanites, study suggests
HEALTH NOTES: You don't need to be surrounded by grass to struggle with hay fever as city-dwellers suffer from worse symptoms, a study suggests (stock photo of man with hay fever). (Source: the Mail online | Health)
Source: the Mail online | Health - February 25, 2023 Category: Consumer Health News Source Type: news
U.S. FDA Approves ALK's Odactra (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents
Odactra is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons 12 through 17 years of age, in addition to adults 18 through 65 years of age
Nearly 50% of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 25, 2023 Category: Drugs & Pharmacology Source Type: news
Study Evaluates Alopecia Areata Features in Hispanic Population Study Evaluates Alopecia Areata Features in Hispanic Population
In the study, the most common comorbidity in patients overall was atopy, including allergic rhinitis, asthma, and/or atopic dermatitis.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 29, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Rhinitis Patients Report Symptomatic Medication Use Rhinitis Patients Report Symptomatic Medication Use
A mobile app used to capture control of allergic rhinitis may favor those who are more tech savvy, say critics.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms? Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms?
Adding tezepelumab to cat allergy shots may provide better, longer-lasting symptom relief than allergy shots alone for patients with allergic rhinitis due to cat allergens, researchers report.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 18, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Immunotherapy for Allergic Rhinitis and Asthma Has Lasting Effects Immunotherapy for Allergic Rhinitis and Asthma Has Lasting Effects
Allergen immunotherapy for allergic rhinitis and asthma is effective long-term, according to real-world evidence and real-world data, researchers in Europe report.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 14, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Mayo Clinic Q and A: Sinusitis and treatment options
DEAR MAYO CLINIC: I have had ongoing nasal congestion and mucus for the past several months. I thought it was allergies, but my doctor says I likely have acute sinusitis brought on by allergic rhinitis. I was advised to try nonprescription medications to relieve my symptoms rather than antibiotics. What is the difference between this and a normal sinus infection, and what are the best treatment options? ANSWER: Acute sinusitis causes the spaces inside your nose —… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 2, 2022 Category: Databases & Libraries Source Type: news
Mayo Clinic Minute: How to get hay fever relief from fall allergies
Autumn is the season of change, with green leaves turning color and temperatures cooling. It's also the season of hay fever, or allergic rhinitis. So how can people with fall allergies get relief? Watch: The Mayo Clinic Minute https://youtu.be/0OEAj1x6L-o Journalists: Broadcast-quality video (1:06) is in the downloads at the end of this post. Please courtesy: "Mayo Clinic News Network." Read the script. "Fall is a very common season for seasonal allergies to kick in," says… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 27, 2022 Category: Databases & Libraries Source Type: news
New Nasal Spray for Seasonal Allergic Rhinitis New Nasal Spray for Seasonal Allergic Rhinitis
Patients with both nasal and ocular symptoms of SAR have a new treatment option that combines olopatadine hydrochloride and mometasone furoate in the form of a nasal spray.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 7, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Miracle ‘farm dust’ pill could prevent childhood allergies
Treatments based on barnyard material and unprocessed milk may be developed by 2027An international team of scientists is working on a “farm dust” treatment to stop childrendeveloping allergies as research reveals the protective benefits of being brought up on a farm can last into adulthood.The study has found evidence that children brought up on family farms have greater protection into early adulthood from allergic rhinitis, a reaction that can cause a runny nose, sneezing and red eyes.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 4, 2022 Category: Science Authors: Jon Ungoed-Thomas Tags: Allergies Medical research Health Science Source Type: news
